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BACKGROUND
Huntington’s disease is an autosomal-dominant neurodegenerative disease caused by 
CAG trinucleotide repeat expansion in HTT, resulting in a mutant huntingtin protein. 
IONIS-HTTRx (hereafter, HTTRx) is an antisense oligonucleotide designed to inhibit 
HTT messenger RNA and thereby reduce concentrations of mutant huntingtin.
METHODS
We conducted a randomized, double-blind, multiple-ascending-dose, phase 1–2a trial 
involving adults with early Huntington’s disease. Patients were randomly assigned 
in a 3:1 ratio to receive HTTRx or placebo as a bolus intrathecal administration every 
4 weeks for four doses. Dose selection was guided by a preclinical model in mice and 
nonhuman primates that related dose level to reduction in the concentration of hunting-
tin. The primary end point was safety. The secondary end point was HTTRx pharmaco-
kinetics in cerebrospinal fluid (CSF). Prespecified exploratory end points included the 
concentration of mutant huntingtin in CSF.
RESULTS
Of the 46 patients who were enrolled in the trial, 34 were randomly assigned to receive 
HTTRx (at ascending dose levels of 10 to 120 mg) and 12 were randomly assigned to 
receive placebo. Each patient received all four doses and completed the trial. Adverse 
events, all of grade 1 or 2, were reported in 98% of the patients. No serious ad-
verse events were seen in HTTRx-treated patients. There were no clinically relevant 
adverse changes in laboratory variables. Predose (trough) concentrations of HTTRx in 
CSF showed dose dependence up to doses of 60 mg. HTTRx treatment resulted in a 
dose-dependent reduction in the concentration of mutant huntingtin in CSF (mean 
percentage change from baseline, 10% in the placebo group and −20%, −25%, −28%, 
−42%, and −38% in the HTTRx 10-mg, 30-mg, 60-mg, 90-mg, and 120-mg dose 
groups, respectively).
CONCLUSIONS
Intrathecal administration of HTTRx to patients with early Huntington’s disease was 
not accompanied by serious adverse events. We observed dose-dependent reductions 
in concentrations of mutant huntingtin. (Funded by Ionis Pharmaceuticals and 
F. Hoffmann–La Roche; ClinicalTrials.gov number, NCT02519036.)
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Huntington’s disease is a progres-sive neurodegenerative disorder inherited as an autosomal-dominant trait, with on-
set typically occurring in mid-adult life and char-
acterized by movement disorder, cognitive de-
cline, and behavioral symptoms.1 Huntington’s 
disease is caused by CAG trinucleotide repeat 
expansion in the huntingtin (HTT) gene, which 
encodes huntingtin protein (HTT).2 The abnor-
mal gene results in the production of gene prod-
ucts, including mutant HTT, containing an ex-
panded polyglutamine tract, which causes neuronal 
dysfunction and death, putatively by means of 
toxic gain-of-function mechanisms.3,4 Current 
treatments for Huntington’s disease are limited 
to therapies to treat symptoms, because no treat-
ment has been shown to prevent onset or to slow 
progression. Given the monogenic nature of 
Huntington’s disease, we sought to inhibit HTT 
expression and thus directly target the primary 
disease mechanism.5
IONIS-HTTRx (also known as ISIS 443139 and 
RG6042; hereafter referred to as HTTRx) is a 
second-generation 2′-O-(2-methoxyethyl) antisense 
oligonucleotide that was designed to reduce con-
centrations of HTT messenger RNA (mRNA). 
HTTRx binds to its cognate mRNA by means of 
Watson–Crick base-pair interactions, triggering 
RNase H1-mediated degradation of the target 
mRNA.6 Antisense oligonucleotide–mediated se-
lective reduction of HTT mRNA leads to lowered 
HTT concentrations and sustained amelioration 
of disease-associated phenotypes in multiple trans-
genic animal models of Huntington’s disease.7 
Long-term administration of HTT-lowering agents 
to nonhuman primates without mutations re-
sulted in a reduction in the HTT concentration 
in central nervous system tissues without adverse 
effects.7,8 Experiments with alternative methods 
that were designed to inhibit HTT expression 
yielded similar effects in animal models of Hun-
tington’s disease,8-10 validating the reduction of 
the HTT concentration as a potentially viable 
disease-modifying therapeutic strategy. We report 
the results of a targeted HTT-lowering agent in 
this phase 1–2a clinical trial of an HTT-targeting 
antisense oligonucleotide administered intrathe-
cally as a bolus in adults with early Huntington’s 
disease.
Me thods
Trial Drug
HTTRx is a chemically modified synthetic oligo-
mer that is perfectly complementary to a 20-nucle-
otide stretch of HTT mRNA. HTTRx binds to HTT 
mRNA by means of Watson–Crick base pairing, 
with hybridization resulting in endogenous 
RNase H1-mediated degradation of the HTT 
mRNA, thus inhibiting translation of the hun-
tingtin protein. The sequence of HTTRx is (5′ to 3′) 
ctocoaogTAACATTGACaococoac, in which capital 
letters represent 2′-deoxyribose nucleosides, and 
small letters 2′-(2-methoxyethyl)ribose nucleo-
sides. Nucleoside linkages that are represented 
with a subscripted “o” are phosphodiester, and 
all others are phosphorothioate. Letters “a” and 
“A” represent adenine, “c” and “C” 5-methylcy-
tosine, “g” and “G” guanine, and “t” and “T” 
thymine nucleobases.
Trial Oversight
The trial was conducted in accordance with the 
principles of the Declaration of Helsinki. The 
trial protocol (available with the full text of this 
article at NEJM.org) and all documentation were 
approved by the institutional review board or 
independent ethics committee at each investiga-
tional site. All the patients provided written in-
formed consent. The trial was sponsored by Ionis 
Pharmaceuticals, which provided the trial agents 
(HTTRx and placebo). Personnel from Ionis Phar-
maceuticals designed the trial in conjunction 
with collaborators from F. Hoffmann–La Roche, 
principal academic investigators, and other dis-
ease experts. An independent data and safety 
monitoring board authorized each dose escala-
tion after unblinded review of safety data and 
consultation with the sponsor, Ionis Pharmaceu-
ticals. The investigators collected the data, which 
were held and maintained by the sponsor. Data 
were analyzed by personnel from the sponsor 
and were interpreted by all the authors. The in-
vestigators vouch for the fidelity of the trial to 
the protocol and protocol amendments. The 
authors vouch for the completeness and accu-
racy of the data. The authors and sponsor made 
the decision to submit the manuscript for pub-
lication.
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Patients
Eligible participants were between 25 and 65 
years of age and had early Huntington’s disease, 
defined as 36 or more CAG repeats in HTT and 
clinical stage 1 disease (Unified Huntington’s 
Disease Rating Scale total functional capacity 
score of 11 to 13, on a scale from 0 to 13, with 
higher scores indicating less functional impair-
ment; a score of 11 to 13 indicates little to no 
functional impairment across the items assessed 
[occupation, finances, domestic chores, activities 
of daily living, and care level]).11 Further details 
of the inclusion and exclusion criteria are pro-
vided in the Supplementary Appendix, available 
at NEJM.org.
Trial Design and End Points
HTTRx-CS1 was a randomized, double-blind, 
placebo-controlled, multicenter, phase 1–2a tri-
al. The trial was performed at nine centers in the 
United Kingdom, Germany, and Canada from 
August 2015 through November 2017. A central-
ized automated randomization system was used 
to assign patients in a 3:1 ratio to receive HTTRx 
or placebo within each of five dose cohorts in an 
ascending-dose design (10 mg, 30 mg, 60 mg, 
90 mg, or 120 mg).
Each patient received four bolus intrathecal 
injections of HTTRx or placebo (artificial cere-
brospinal fluid) at 4-week intervals; subsequent-
ly, there was a 4-month follow-up period during 
which no trial agent was administered. A cere-
brospinal fluid (CSF) sample was obtained be-
fore each administration of HTTRx or placebo and 
either 4 or 8 weeks after the last dose was ad-
ministered (Fig. 1). Investigators, patients, the 
sponsor (Ionis Pharmaceuticals), and its col-
laborator (F. Hoffmann–LaRoche) were unaware 
of the trial-group assignments for the duration of 
the trial.
The primary end point was the safety of HTTRx 
treatment. Safety evaluations included physical 
examination, neurologic examination, the Colum-
bia Suicide Severity Rating Scale, laboratory as-
sessments, vital signs, electrocardiograms, and 
safety neuroimaging sequences. At each trial 
visit, patients were queried for other changes in 
health status in an open-ended fashion.
The secondary end point was the character-
ization of the pharmacokinetics of HTTRx in CSF. 
Exploratory end points were the characterization 
of the pharmacokinetics of HTTRx in plasma and 
exploration of the effects of HTTRx on pharma-
codynamic biomarkers and clinical end points 
relevant in Huntington’s disease, including the 
concentrations of mutant HTT and neurofila-
ment light protein in the CSF, ventricular vol-
ume, and the composite cognitive score on the 
Huntington’s Disease Cognitive Assessment Bat-
tery. After the completion of the trial, partici-
pants were offered the opportunity to enroll in a 
15-month, open-label extension study (Clinical-
Trials.gov number, NCT03342053) evaluating the 
effects of intrathecal administration of 120 mg 
of HTTRx either monthly or every other month.
Measurement of Cerebral Volume
We obtained 3-T T1-weighted structural mag-
netic resonance imaging (MRI) scans of the 
head and transferred these data to an indepen-
dent image-analysis provider that performed 
quality-control, processing, and volumetric analy-
ses, blinded to trial-group status, according to 
established methods.12 Whole-brain and regional 
volume changes were calculated with the use of 
the boundary shift integral, a semiautomated 
Figure 1. Trial Design.
At the conclusion of the screening period, eligible patients were randomly 
assigned in a 3:1 ratio to receive the antisense oligonucleotide drug HTTRx 
or placebo. Cerebrospinal fluid (CSF) samples were obtained before the 
administration of the trial agent on days 1, 29, 57, and 85. The CSF sample 
on day 1 served as the baseline sample, and the CSF samples on days 29, 
57, and 85 served as 28-day post-dose trough samples. One sample was 
obtained from each patient after the completion of the regimen, either on 
day 113 or day 141 according to randomized assignment. The CSF sample 
that was obtained on day 113 served as a 28-day post–last dose sample; 
the sample obtained on day 141 served as a 56-day post–last dose sample. 
Dotted lines indicate the relationship between each dose and the subse-
quent CSF sample.
1 29 57 85 113 141 197
Trial Day
Screening ≤6 wk
End
of
trial
DoseCSF sample
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method that determines volume change from 
three-dimensional shift between paired images 
of a regional boundary.
Statistical Analysis
The primary objective of the trial was the evalu-
ation of the safety of HTTRx treatment (primary 
end point). Adverse events and serious adverse 
events during the trial, laboratory tests (in blood 
and CSF), vital signs, electrocardiographic mea-
sures, and observations from the Columbia 
Suicide Severity Rating Scale were summarized 
according to trial group. Where possible, phar-
macokinetic variables were assessed for HTTRx 
in CSF (secondary end point) and plasma (explor-
atory end point). Analyses of pharmacodynamic 
biomarkers and clinical end points were summa-
rized according to trial group, and the HTTRx-
treated groups were compared with the placebo 
group.
The treatment differences and 95% confidence 
intervals for changes in the mutant HTT concen-
tration in CSF were Hodges–Lehmann estima-
tions that were based on the Wilcoxon rank-sum 
test or were obtained with the use of analysis of 
variance, depending on the normality of the data. 
Relationships between reductions in the concen-
tration of mutant HTT in CSF and clinical out-
comes were explored in a post hoc analysis with 
the use of Spearman’s correlation coefficient, 
and the 95% confidence interval of the correla-
tion coefficient was based on Fisher’s z transfor-
mation. Because of the exploratory nature of this 
trial, adjustments for multiplicity of testing were 
not used. Interpretation of HTTRx effects on mu-
tant HTT in tissue was based on the extent of 
reduction of the mutant HTT concentration in 
CSF and a linked pharmacokinetic and pharma-
codynamic clearance model that was based on 
data collected in human mutant HTT–transgenic 
mice and nonhuman primates (see the Supple-
mentary Appendix).
R esult s
Patients
From August 2015 through April 2017, a total of 
52 patients were screened for eligibility, and 46 
patients underwent randomization according to 
the protocol. All the patients received all sched-
uled doses of the assigned trial agent (HTTRx or 
placebo), and all the patients who had undergone 
randomization completed the trial according to 
the protocol. (A diagram of the flow of patients 
through the trial is provided in Fig. S3 in the 
Supplementary Appendix.) The characteristics of 
the patients at baseline were representative of 
early-stage Huntington’s disease and were simi-
lar across the trial groups (Table 1).
Primary End Point of Safety
The incidence of adverse events was similar 
among patients receiving HTTRx and those re-
ceiving placebo (Table 2). Adverse events were 
reported in 98% of the patients; all events were 
mild (83%) or moderate (17%) in severity. The 
most commonly reported adverse events in pa-
tients who received HTTRx were procedural pain 
and post–dural-puncture headache, which oc-
curred after approximately 10% of lumbar punc-
tures and had no apparent relationship to trial 
duration or dose. There was no evidence of an 
increased risk of post–dural-puncture headache 
with successive lumbar punctures. All post–dural-
puncture headaches resolved (median duration, 
2 days), and no blood patches were used. Very 
few adverse events (6%) were considered by the 
investigators (who were unaware of the trial-group 
assignment) to be related to HTTRx or placebo, 
and most of the related events (83%) were also 
considered to be related to a trial procedure. 
There were no deaths, dose-limiting adverse 
events, discontinuations of regimens, or delays 
in trial-agent administration during the trial.
The only serious adverse event was an inpa-
tient admission of a patient in the placebo group 
for observation of a mild post–dural-puncture 
headache. Neither suicidal behavior nor serious 
suicidal ideation emerged in any patient during 
the trial. One case of a mildly increased CSF 
leukocyte count (20 to 23 cells per cubic milli-
meter, measured in triplicate) without associated 
symptoms was observed 8 weeks after the last 
60-mg dose of HTTRx was administered; the 
clinical safety MRI and electroencephalographic 
results were normal. The asymptomatic elevation 
persisted throughout the post-treatment period 
and resolved before the patient’s initiation of 
treatment in the extension study, 64 weeks after 
the last dose in this trial.
Secondary End Point
HTTRx was measurable in the CSF of most pa-
tients who received doses of 30 mg or more. 
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Trough concentrations increased with increasing 
dose, from below the limit of quantification at 
the 10-mg dose through the 60-mg dose, with a 
plateau in the concentration in CSF beyond the 
60-mg dose (Fig. 2A). No accumulation of HTTRx 
in CSF was observed over time.
Exploratory End Points
Plasma Concentrations of HTT
Rx
The median peak plasma concentrations of 
HTTRx were reached within 4 hours after the 
bolus intrathecal administration and declined to 
less than 30% of the peak concentration by 24 
hours after administration. The concentration of 
HTTRx in plasma increased approximately pro-
portionally to the dose over the explored dose 
range (Fig. 2B). There was no evidence of accu-
mulation of concentration in plasma 24 hours 
after dose administration over the course of the 
trial, and there was a minor increase (<20%) in 
the peak concentration at the 120-mg dose level.
Concentrations of Mutant HTT in CSF
In patients who received HTTRx, there were dose-
dependent decreases in the concentration of 
mutant HTT in CSF at the last available 28-day 
post-dose sampling point (mean percentage 
change from baseline of −20%, −25%, −28%, 
−42%, and −38% in the HTTRx 10-mg, 30-mg, 
60-mg, 90-mg, and 120-mg dose groups, respec-
tively), with a maximum reduction of 63% in an 
individual patient (in the 120-mg cohort). In 
patients who received placebo, the mean per-
centage change from baseline was an increase of 
10% in the concentration of mutant HTT in CSF 
(Fig. 3A and 3B, and Table S1 in the Supplemen-
tary Appendix). Steady-state maximal reduction 
of the concentration of mutant HTT in CSF did 
Characteristic
Placebo 
(N = 12) HTTRx
All 
(N = 34)
10 mg 
(N = 3)
30 mg 
(N = 6)
60 mg 
(N = 6)
90 mg 
(N = 9)
120 mg 
(N = 10)
Age — yr 49±10 46±10 44±17 53±7 43±11 46±10 45±10
Female sex — no. (%) 4 (33) 14 (41) 1 (33) 1 (17) 3 (50) 3 (33) 6 (60)
White race — no. (%)† 11 (92) 32 (94) 3 (100) 5 (83) 6 (100) 9 (100) 9 (90)
No. of CAG repeats 44±2 44±3 46±6 43±2 45±2 44±3 45±4
Montreal Cognitive Assessment score‡ 25±2 26±3 26±4 27±2 26±3 26±3 26±3
Total functional capacity score  
— no. (%)§
11 6 (50) 9 (26) 0 2 (33) 2 (33) 2 (22) 3 (30)
12 4 (33) 15 (44) 1 (33) 4 (67) 3 (50) 4 (44) 3 (30)
13 2 (17) 10 (29) 2 (67) 0 1 (17) 3 (33) 4 (40)
Total motor score¶ 24±7 22±10 21±7 20±13 25±13 22±10 21±9
Independence scale score‖ 89±8 90±8 93±6 88±11 86±8 93±8 90±6
Disease-burden score** 398.4±50.1 383.7±66.0 385.2±109.1 366.7±50.8 383.8±34.3 364.5±68.7 410.8±75.1
Concentration of mutant HTT in CSF 
— fmol/liter
109±43 110±46 144±50 120±45 117±30 105±65 96±35
*  Plus–minus values are means ±SD. Patients were assigned to receive either placebo or ascending doses of the antisense oligonucleotide 
drug HTTRx. Percentages may not total 100 because of rounding. CSF denotes cerebrospinal fluid, and HTT huntingtin protein.
†  Race was reported by the patient.
‡  Scores on the Montreal Cognitive Assessment range from 0 to 30, with higher scores indicating better cognitive function.
§  Total functional capacity scores on the Unified Huntington’s Disease Rating Scale range from 0 to 13, with higher scores indicating less 
functional impairment. A score of 11 to 13 indicates little to no functional impairment across the items assessed (occupation, finances, 
domestic chores, activities of daily living, and care level).
¶  Total motor scores range from 0 to 124, with lower scores indicating less impairment.
‖  Independence scale scores range from 0 to 100, with higher scores indicating higher levels of independence.
**  The disease-burden score is calculated as follows: (CAG repeat length − 35.5) × age in years.13 Larger numbers represent a higher burden  
of disease.
Table 1. Characteristics of the Patients at Baseline.*
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not appear to have been reached during the 
3-month trial period (Fig. 3A and 3C).
Additional Exploratory Outcomes
Functional, cognitive, psychiatric, and neurologic 
clinical outcomes were generally unchanged at 
the dose-group level during the trial, and no 
meaningful differences were observed between 
patients who received placebo and patients who 
received HTTRx, regardless of the dose level 
(Table S2 in the Supplementary Appendix). The 
ventricular volume showed dose-dependent and 
time-dependent increases at day 113 and at day 
197, without adverse consequences, in the 90-mg 
and 120-mg dose groups that were greater than 
those in the placebo group (boundary shift inte-
grals at days 113 and 197 were 2.6 ml and 5.0 ml, 
respectively, in the 90-mg group and 2.3 ml and 
5.3 ml, respectively, in the 120-mg group).
Elevations of the concentration of neurofila-
Event Grade 1 Grade 2 Grade 3 or 4
HTTRx 
Groups  
(N = 34)
Placebo 
Group 
(N = 12)
HTTRx 
Groups  
(N = 34)
Placebo 
Group 
(N = 12)
HTTRx 
Groups  
(N = 34)
Placebo 
Group 
(N = 12)
number of patients with event (percent)
Any adverse event 20 (59) 7 (58) 13 (38) 5 (42) 0 0
Any serious adverse event 0 1 (8) 0 0 0 0
Event according to system organ class or preferred term
Injury, poisoning, or procedural complication 19 (56) 7 (58) 7 (21) 4 (33) 0 0
Procedural pain 17 (50) 4 (33) 2 (6) 2 (17) 0 0
Post–lumbar-puncture syndrome 8 (24) 4 (33) 4 (12) 1 (8) 0 0
Fall 7 (21) 2 (17) 0 1 (8) 0 0
Skin abrasion 5 (15) 1 (8) 0 0 0 0
Infection or infestation 21 (62) 4 (33) 2 (6) 2 (17) 0 0
Nasopharyngitis 7 (21) 0 0 2 (17) 0 0
Upper respiratory tract infection 3 (9) 1 (8) 1 (3) 0 0 0
Bronchitis 2 (6) 0 1 (3) 0 0 0
Influenza 2 (6) 0 1 (3) 0 0 0
Rhinovirus infection 3 (9) 0 0 0 0 0
Nervous system disorder 9 (26) 4 (33) 3 (9) 3 (25) 0 0
Headache 4 (12) 3 (25) 2 (6) 3 (25) 0 0
Hypoesthesia 3 (9) 0 0 0 0 0
Musculoskeletal or connective-tissue disorder 9 (26) 4 (33) 1 (3) 1 (8) 0 0
Arthralgia 4 (12) 2 (17) 0 0 0 0
Back pain 3 (9) 1 (8) 1 (3) 0 0 0
General disorder or administration-site condition 5 (15) 2 (17) 1 (3) 0 0 0
Fatigue 4 (12) 0 1 (3) 0 0 0
Gastrointestinal disorder 5 (15) 1 (8) 1 (3) 0 0 0
Toothache 2 (6) 0 1 (3) 0 0 0
Vascular disorder 3 (9) 0 0 0 0 0
Hematoma 3 (9) 0 0 0 0 0
*  Shown are adverse events that occurred from the first dose of trial agent through the end of the trial. Each adverse event was rated as mild, 
moderate, or severe, corresponding to grades of 1, 2, and 3, respectively. In addition, serious adverse events were rated as life-threatening 
(grade 4) or not life-threatening. At each level of summation (overall and according to system organ class or preferred term), patients for 
whom more than one adverse event was reported were counted only once according to the most severe category of event.
Table 2. Adverse Events Reported in at Least Three Patients Receiving HTTRx, According to Grade.*
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ment light protein in CSF occurred in some pa-
tients in the 90-mg and 120-mg cohorts at day 
113 or day 141 (i.e., 1 or 2 months after cessa-
tion of the regimen, respectively), but there were 
no associated adverse events or safety changes 
on MRI (Fig. S4 in the Supplementary Appen-
dix). By the start of the extension study (7 to 27 
months after the final doses were administered 
in this trial), the concentrations of neurofilament 
light protein in the CSF had generally returned 
to pretrial concentrations. During the extension 
study, the concentrations rose with a time 
course and magnitude that were similar to those 
observed in this trial and then decreased at later 
time points despite continued treatment (unpub-
lished data).
Post Hoc Analyses
In parallel with this trial, the composite Unified 
Huntington Disease Rating Scale (cUHDRS) was 
developed to serve as a measure of clinical pro-
gression in early Huntington’s disease.14 We ex-
amined the relationships between the degree of 
lowering of the CSF concentration of mutant 
HTT and changes in the cUHDRS score and its 
four components and observed correlations be-
Figure 2. HTTRx Exposure.
Panel A shows the maximum predose (i.e., 28-day trough) concentration of the antisense oligonucleotide drug HTTRx 
in CSF according to dose group (placebo or the various HTTRx dose groups). Panel B shows the mean concentration 
of HTTRx in plasma, according to dose group, over the 24-hour periods after the administration of the first dose 
(left side; day 1) and fourth dose (right side; day 85). Error bars indicate the standard error. Further discussion of 
the observed concentrations of HTTRx is provided in the Supplementary Appendix.
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tween reduction in the CSF concentration of 
mutant HTT and improvements in the cUHDRS 
score and two of its components (Fig. S5 in the 
Supplementary Appendix). These correlations 
should be interpreted with caution, because the 
tests were not prespecified and the coefficients 
of correlation were not adjusted for multiple 
testing.
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Discussion
A regimen of four repeated monthly bolus intra-
thecal administrations of HTTRx, an HTT mRNA-
targeting antisense oligonucleotide, to adults 
with early Huntington’s disease was not accom-
panied by any serious adverse events. The inter-
vention resulted in a dose-dependent reduction 
in the concentration of mutant HTT, the protein 
that putatively causes Huntington’s disease, in 
the CSF. Given the results of only this trial, we 
do not know whether this reduction reflects a 
reduction in the concentration of mutant HTT in 
the central nervous system, although preclinical 
studies support the hypothesis that concentra-
tions of mutant HTT in the CSF reflect the con-
centrations of mutant HTT in central nervous 
system tissue (see the Supplementary Appendix, 
as well as Southwell et al.15). Although the posi-
tive effects of sustained lowering of the concen-
tration of mutant HTT on motor function and 
survival in mouse models of Huntington’s dis-
ease7,8 provided a rationale for the development 
of an HTT-targeting antisense oligonucleotide, 
larger studies of greater duration will be needed 
to determine whether HTTRx-mediated reduction 
of the concentration of mutant HTT in CSF is 
associated with a treatment effect on the disease 
course, which is typically slow, with changes on 
standard outcomes generally occurring over a 
period of years.
The ventricular volume showed apparent dose-
dependent and time-dependent increases during 
the trial with no corresponding changes in whole-
brain volume. Slow, progressive whole-brain at-
rophy (i.e., irreversible loss of brain tissue) and 
ventricular expansion are characteristic features 
of Huntington’s disease,16 and neuroinflamma-
tion is a known phenomenon in patients with 
the disease.17,18 Although pseudoatrophy (i.e., ven-
tricular expansion due to resolution of inflam-
matory edema and gliosis) has been described in 
clinical studies of multiple sclerosis and Alzhei-
mer’s disease, it has been a challenge to differ-
entiate between treatment-induced pseudoatrophy 
and disease-related atrophy,19-24 and we have not 
assessed the effect of HTTRx treatment on inflam-
mation or gliosis in humans or animal models.
The putative neuronal injury marker, the con-
centration of neurofilament light protein in the 
CSF,25 showed apparent dose-dependent and 
time-dependent increases during the trial and 
reversed after the cessation of the trial regimen 
and also after transient increases during the 
extension study. To our knowledge, there are no 
published longitudinal studies of neurofilament 
light protein in the CSF of persons with Hun-
tington’s disease, and so the magnitude of in-
crease that corresponds with an adverse out-
come is unknown. The values that we observed 
in this trial are within the range of values ob-
served in a cross-sectional study involving pa-
tients with Huntington’s disease.26
In conclusion, we found that the antisense 
oligonucleotide drug HTTRx reduced the concen-
tration of mutant HTT in the CSF of persons 
with Huntington’s disease. More generally, we 
found antisense-mediated protein suppression 
in the central nervous system of patients with a 
neurodegenerative disease.
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Figure 3 (facing page). Effect of HTTRx on CSF 
 Concentrations of Mutant Huntingtin Protein (HTT).
Panel A shows the concentrations of mutant HTT in 
CSF over time for individual patients in each dose group; 
absolute values, measured in femtomoles per liter, are 
shown in the top graphs, and the percentage changes 
from baseline (dotted line) are shown in the bottom 
graphs. Arrowheads indicate the 4 days on which HTTRx 
or placebo was administered. A discussion of the indi-
vidual patient data that were observed in the 120-mg 
dose group is provided in the Supplementary Appendix. 
Panel B shows the percentage change in the concentra-
tion of mutant HTT in CSF from baseline (dotted line) 
to the last available time point 28 days after the previous 
dose (i.e., either day 113 for the patients who underwent 
CSF sampling at day 113 or day 85 for the other patients). 
Circles indicate individual patients, and horizontal lines 
indicate group means; 95% confidence intervals are 
also shown for the active-agent dose groups. Panel C 
shows the mean concentration of mutant HTT in CSF 
(left) and the mean percentage change from baseline 
(right) over time according to dose group. Error bars 
indicate the standard deviation. Samples from days 
113 and 141 were each obtained in a randomized sub-
group of patients (dotted lines).
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